Key result
Correct management of pulmonary hypertension from left heart disease requires optimizing treatment of the underlying left heart disease rather than using pulmonary vasodilators.
Management of WHO Group 2 pulmonary hypertension should focus on optimizing underlying left heart disease rather than using pulmonary vasodilators.
Supports prioritizing underlying left heart disease management in Group 2 PH; leaves open need for dedicated randomized trials.
Background: Left heart disease (LHD) is the most common cause of pulmonary hypertension (PH) and is associated with poor patient outcomes, especially among patients undergoing heart transplant evaluation. Implications for clinicians: Left heart disease should be considered in all patients undergoing an evaluation for PH. Correct management of PH from LHD is to optimize treatment of LHD. Pulmonary vasodilators used to treat pulmonary arterial hypertension should not be used in patients with PH from LHD. Conclusions: Additional research is needed to better understand how PH develops in patients with LHD and to investigate the role for treatment targeting PH in these patients.
No takes yet. Share an insight, caveat, or question.
Barnett et al. (2015) conducted a review in WHO Group 2 Pulmonary Hypertension Due to Left Heart Disease. Pulmonary vasodilators was evaluated. Correct management of pulmonary hypertension from left heart disease requires optimizing treatment of the underlying left heart disease rather than using pulmonary vasodilators.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: